AbbVie Inc. (ABBV)
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. NYSE: ABBV is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement pertains to Gubra's experimental weight loss drug, which is in a Phase 1 trial.
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
So, you want to invest in AbbVie (ABBV 0.14%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?
3 Dividend Stocks to Buy for Reliable Passive Income
You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037, which could cut benefits to about 76% of what people get now.
Only Have $500? 3 No-Brainer Stocks to Buy Right Now
Forget the old adage “it takes money to make money.
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million upfront for GUBamy, with potential milestones up to $1.875 billion, and royalties on net sales. Amylin analogs like GUBamy offer promising weight loss effects (albeit not at the levels of leading incretin therapies), with potentially much better GI tolerability, lean mass preservation and cardiovascular safety.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.
I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.
Why AbbVie (ABBV) Dipped More Than Broader Market Today
In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.
AbbVie Inc. (ABBV) Leerink Partners Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV ) Leerink Partners Global Healthcare Conference March 11, 2025 8:40 AM ET Company Participants Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - EVP, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Rob Michael - Chief Executive Officer Conference Call Participants David Risinger - Leerink Partners David Risinger All right. Good morning, everybody.
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.
